{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:45Z","timestamp":1789117725847,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41030-026-00376-9","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:29:28Z","timestamp":1787560168000},"page":"733-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-573X","authenticated-orcid":false,"given":"Javier","family":"de Miguel-D\u00edez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Callejas-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja G.","family":"Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Gonz\u00e1lez-Villaescusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salud","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"376_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02074-z","volume":"22","author":"DC Marshall","year":"2001","unstructured":"Marshall DC, Al Omari O, Goodall R, et al. Trends in prevalence, mortality, and disability-adjusted life-years relating to chronic obstructive pulmonary disease in Europe: an observational study of the Global Burden of Disease database, 2001\u20132019. BMC Pulm Med. 2001;22:289. https:\/\/doi.org\/10.1186\/s12890-022-02074-z.","journal-title":"BMC Pulm Med"},{"key":"376_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1514846","author":"K Simmalee","year":"2025","unstructured":"Simmalee K, Kawamatawong T, Vitte J, et al. Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review. Front Med (Lausanne). 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1514846.","journal-title":"Front Med (Lausanne)"},{"key":"376_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2025.2583274","author":"S Gao","year":"2025","unstructured":"Gao S, Liu X. Type 2 inflammatory phenotypes in chronic obstructive pulmonary disease and asthma: similarities and differences. Immunol Invest. 2025. https:\/\/doi.org\/10.1080\/08820139.2025.2583274.","journal-title":"Immunol Invest"},{"key":"376_CR4","unstructured":"GEMA 5.5 LA NUEVA GU\u00cdA ESPA\u00d1OLA PARA EL MANEJO DEL ASMA | SEPAR. https:\/\/www.separ.es\/gema-5.5-asma. Accessed 1 June 2026."},{"key":"376_CR5","unstructured":"2026 GINA Strategy Report - Global Initiative for Asthma - GINA. https:\/\/ginasthma.org\/2026-gina-strategy-report\/. Accessed 1 June 2026."},{"key":"376_CR6","unstructured":"Agusti A, Criner G, Halpin D, et al. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2026 Report 2025. www.goldcopd.org. Accessed 19 June 2026"},{"key":"376_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/J.ARBRES.2025.10.008","volume":"61","author":"M Miravitlles","year":"2025","unstructured":"Miravitlles M, Calle M, Molina J, et al. Update 2025 of the Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol. 2025;61:725\u2013808. https:\/\/doi.org\/10.1016\/J.ARBRES.2025.10.008.","journal-title":"Arch Bronconeumol"},{"key":"376_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/RCCM.202301-0149OC","volume":"208","author":"CC L\u00f3pez","year":"2023","unstructured":"L\u00f3pez CC, Santos AS, Castellano AL, et al. Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208:155\u201362. https:\/\/doi.org\/10.1164\/RCCM.202301-0149OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"376_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697\u2013700. https:\/\/doi.org\/10.1183\/09031936.00162414.","journal-title":"Eur Respir J"},{"key":"376_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.46747\/CFP.6709661","volume":"67","author":"AD D\u2019Urzo","year":"2021","unstructured":"D\u2019Urzo AD, Price D, Kardos P, et al. Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care. Can Fam Physician. 2021;67:661\u20137. https:\/\/doi.org\/10.46747\/CFP.6709661.","journal-title":"Can Fam Physician"},{"issue":"1","key":"376_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/S12890-022-01823-4","volume":"22","author":"AV Gayle","year":"2022","unstructured":"Gayle AV, Minelli C, Quint JK. Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. BMC Pulm Med. 2022;22(1):28. https:\/\/doi.org\/10.1186\/S12890-022-01823-4.","journal-title":"BMC Pulm Med"},{"key":"376_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/J.CCM.2013.09.010","volume":"35","author":"DS Postma","year":"2014","unstructured":"Postma DS, Reddel HK, ten Hacken NHT, et al. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med. 2014;35:143\u201356. https:\/\/doi.org\/10.1016\/J.CCM.2013.09.010.","journal-title":"Clin Chest Med"},{"key":"376_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0088-2024","author":"B Gyawali","year":"2025","unstructured":"Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025. https:\/\/doi.org\/10.1183\/16000617.0088-2024.","journal-title":"Eur Respir Rev"},{"key":"376_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041546","author":"F Menzella","year":"2023","unstructured":"Menzella F. Baseline characteristics of patients enrolled in clinical trials of biologics for severe asthma as potential predictors of outcomes. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12041546.","journal-title":"J Clin Med"},{"key":"376_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15101245","author":"KM Phillips","year":"2025","unstructured":"Phillips KM, Lavere PF, Hanania NA, et al. The emerging biomarkers in chronic obstructive pulmonary disease: a narrative review. Diagnostics (Basel). 2025. https:\/\/doi.org\/10.3390\/diagnostics15101245.","journal-title":"Diagnostics (Basel)"},{"key":"376_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","volume":"206","author":"D Singh","year":"2022","unstructured":"Singh D, Agusti A, Martinez FJ, et al. Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 review. Am J Respir Crit Care Med. 2022;206:17\u201324. https:\/\/doi.org\/10.1164\/rccm.202201-0209PP.","journal-title":"Am J Respir Crit Care Med"},{"key":"376_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/nejmoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389:205\u201314. https:\/\/doi.org\/10.1056\/nejmoa2303951.","journal-title":"N Engl J Med"},{"key":"376_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(25)00044-X","volume":"13","author":"SA Christenson","year":"2025","unstructured":"Christenson SA, Hanania NA, Bhatt SP, et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025;13:687\u201397. https:\/\/doi.org\/10.1016\/S2213-2600(25)00044-X.","journal-title":"Lancet Respir Med"},{"key":"376_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/17476348.2025.2453652","volume":"19","author":"BG Cosio","year":"2025","unstructured":"Cosio BG, Palou A, L\u00f3pez M, et al. Towards the integrated care of COPD, asthma and bronchiectasis: description and objectives of a treatable trait-based complex obstructive airway disease unit. Expert Rev Respir Med. 2025;19:87\u201395. https:\/\/doi.org\/10.1080\/17476348.2025.2453652.","journal-title":"Expert Rev Respir Med"},{"key":"376_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2026.05.006","author":"A Maldonado","year":"2026","unstructured":"Maldonado A, del Campo-Grijalba M, Angelina A, et al. Type 2 endotypes in airway diseases. Arch Bronconeumol. 2026. https:\/\/doi.org\/10.1016\/j.arbres.2026.05.006.","journal-title":"Arch Bronconeumol"},{"key":"376_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"key":"376_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01291-2018","author":"AD Doyle","year":"2019","unstructured":"Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.01291-2018.","journal-title":"Eur Respir J"},{"key":"376_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"key":"376_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1084\/JEM.194.6.809","volume":"194","author":"CG Lee","year":"2001","unstructured":"Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001;194:809\u201321. https:\/\/doi.org\/10.1084\/JEM.194.6.809.","journal-title":"J Exp Med."},{"key":"376_CR25","doi-asserted-by":"publisher","DOI":"10.4161\/TISB.24333","volume":"1","author":"B Saatian","year":"2013","unstructured":"Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers. 2013;1:e24333. https:\/\/doi.org\/10.4161\/TISB.24333.","journal-title":"Tissue Barriers"},{"key":"376_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1172\/JCI10458","volume":"106","author":"T Zheng","year":"2000","unstructured":"Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106:1081\u201393. https:\/\/doi.org\/10.1172\/JCI10458.","journal-title":"J Clin Invest"},{"key":"376_CR27","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1172\/JCI64896","volume":"122","author":"YG Alevy","year":"2012","unstructured":"Alevy YG, Patel AC, Romero AG, et al. IL-13\u2013induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest. 2012;122:4555\u201368. https:\/\/doi.org\/10.1172\/JCI64896.","journal-title":"J Clin Invest"},{"key":"376_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1183\/20734735.026410","volume":"7","author":"PJ Barnes","year":"2011","unstructured":"Barnes PJ, Barnes PJ. Similarities and differences in inflammatory mechanisms of asthma and COPD. Breathe (Sheff). 2011;7:229\u201338. https:\/\/doi.org\/10.1183\/20734735.026410.","journal-title":"Breathe (Sheff)"},{"key":"376_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ALL.14016","volume":"75","author":"L George","year":"2020","unstructured":"George L, Taylor AR, Esteve-Codina A, et al. Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy. 2020;75:370\u201380. https:\/\/doi.org\/10.1111\/ALL.14016.","journal-title":"Allergy"},{"key":"376_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/FALGY.2022.957106","author":"MC Marcos","year":"2022","unstructured":"Marcos MC, Cisneros Serrano C. What is the added value of FeNO as T2 biomarker? Front Allergy. 2022. https:\/\/doi.org\/10.3389\/FALGY.2022.957106.","journal-title":"Front Allergy"},{"key":"376_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/J.ARBRES.2021.11.006","volume":"58","author":"B Alc\u00e1zar-Navarrete","year":"2022","unstructured":"Alc\u00e1zar-Navarrete B, D\u00edaz-Lopez JM, Garc\u00eda-Flores P, et al. T2 biomarkers as predictors of exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2022;58:595\u2013600. https:\/\/doi.org\/10.1016\/J.ARBRES.2021.11.006.","journal-title":"Arch Bronconeumol"},{"key":"376_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMOA1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396. https:\/\/doi.org\/10.1056\/NEJMOA1804092.","journal-title":"N Engl J Med"},{"key":"376_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","volume":"13","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13:234\u201343. https:\/\/doi.org\/10.1016\/S2213-2600(24)00409-0.","journal-title":"Lancet Respir Med"},{"key":"376_CR34","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2147\/COPD.S294333","volume":"16","author":"ID Pavord","year":"2021","unstructured":"Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755\u201370. https:\/\/doi.org\/10.2147\/COPD.S294333.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"376_CR35","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMOA2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392:1710\u201320. https:\/\/doi.org\/10.1056\/NEJMOA2413181.","journal-title":"N Engl J Med"},{"key":"376_CR36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMOA1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381:1023\u201334. https:\/\/doi.org\/10.1056\/NEJMOA1905248.","journal-title":"N Engl J Med"},{"key":"376_CR37","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00092-2020","author":"P Alter","year":"2020","unstructured":"Alter P, Orszag J, Kellerer C, et al. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res. 2020. https:\/\/doi.org\/10.1183\/23120541.00092-2020.","journal-title":"ERJ Open Res"},{"key":"376_CR38","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.jaip.2021.01.033","volume":"9","author":"L P\u00e9rez de Llano","year":"2021","unstructured":"P\u00e9rez de Llano L, D\u00e1vila I, Mart\u00ednez-Morag\u00f3n E, et al. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score. J Allergy Clin Immunol Pract. 2021;9:2725\u201331. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.033.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"376_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/J.OPRESP.2022.100192","volume":"4","author":"FJ Alvarez-Guti\u00e9rrez","year":"2022","unstructured":"Alvarez-Guti\u00e9rrez FJ, Blanco-Aparicio M, Casas-Maldonado F, et al. [Documento de consenso de asma grave en adultos. Actualizaci\u00f3n 2022]. Open Respir Arch. 2022;4:100192. https:\/\/doi.org\/10.1016\/J.OPRESP.2022.100192.","journal-title":"Open Respir Arch"},{"key":"376_CR40","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/COPD.S178149","volume":"13","author":"JJ Soler-Catalu\u00f1a","year":"2018","unstructured":"Soler-Catalu\u00f1a JJ, Marzo M, Catal\u00e1n P, et al. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719\u201331. https:\/\/doi.org\/10.2147\/COPD.S178149.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"376_CR41","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2147\/COPD.S71370","volume":"9","author":"JJ Soler-Catalu\u00f1a","year":"2014","unstructured":"Soler-Catalu\u00f1a JJ, Alc\u00e1zar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397\u2013405. https:\/\/doi.org\/10.2147\/COPD.S71370.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"376_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2025.06.003","author":"JJ Soler-Catalu\u00f1a","year":"2025","unstructured":"Soler-Catalu\u00f1a JJ, Villagrasa M, Catal\u00e1n P, et al. Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: the RADAR score. Arch Bronconeumol. 2025. https:\/\/doi.org\/10.1016\/j.arbres.2025.06.003.","journal-title":"Arch Bronconeumol"},{"key":"376_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2026.108718","volume":"254","author":"M Calle Rubio","year":"2026","unstructured":"Calle Rubio M, Soler-Catalu\u00f1a JJ, L\u00f3pez Campos JL, et al. Clinical protocol for the use of biologic therapy in COPD. Respir Med. 2026;254:108718. https:\/\/doi.org\/10.1016\/j.rmed.2026.108718.","journal-title":"Respir Med"},{"key":"376_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccl.2021.12.005","volume":"40","author":"P Pellicori","year":"2022","unstructured":"Pellicori P, Cleland JGF, Clark AL. Chronic obstructive pulmonary disease and heart failure: a breathless conspiracy. Cardiol Clin. 2022;40:171\u201382. https:\/\/doi.org\/10.1016\/j.ccl.2021.12.005.","journal-title":"Cardiol Clin"},{"key":"376_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12325-020-01577-7","volume":"38","author":"JR Hurst","year":"2021","unstructured":"Hurst JR, Winders T, Worth H, et al. A patient charter for chronic obstructive pulmonary disease. Adv Ther. 2021;38:11\u201323. https:\/\/doi.org\/10.1007\/s12325-020-01577-7.","journal-title":"Adv Ther"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00376-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:43:58Z","timestamp":1789116238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00376-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["376"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00376-9","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Javier de Miguel-D\u00edez has received grants and honoraria from Abbott, AstraZeneca, BIAL, Boehringer Ingelheim, Chiesi, FAES, Gebro, GSK, Janssen, Menarini, Novartis, Sanofi, Roche, Teva, Pfizer, and Zamb\u00f3n. Francisco Javier Callejas-Gonz\u00e1lez has received grants and honoraria from Astra Zeneca, Gebro Pharma, GlaxoSmithKline, and Bial. Chiesi, Grifols, Sanofi Genzyme and Menarini. Cruz Gonz\u00e1lez-Villaescusa has received grants and honoraria from AstraZeneca, BIAL, Boehringer Ingelheim, Chiesi, FAES, Gebro, GSK, Menarini, Pari, Sanofi, Teva, Pfizer, and Zamb\u00f3n. Borja G. Cos\u00edo has received grants, travel support and speaker fees from AstraZeneca, BIAL, Chiesi, FAES, Gebro, GSK, Menarini, Sanofi, and Teva. Salud Santos has received grants, travel support and speaker fees from Amb\u00fa, AstraZeneca, BIAL, Chiesi, Gebro, GSK, Menarini, MSD, and Sanofi. Marina Blanco-Aparicio has received honoraria from AstraZeneca, Sanofi-Regeneron, GSK, Chiesi, BIAL, Vertex, Teva, Carlos Cabrera has received grants and honoraria from Astra Zeneca, Gebro Pharma, GlaxoSmithKline, Bial, Chiesi, Grifols, Sanofi Genzyme, Zambon, and Menarini. Sanofi has funded the BRIDGE project, and members of the steering committee have received honoraria for their contribution to the project, excluding this publication. The steering committee entirely drives the direction and content of the project.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}